Jump to content

Guardant Health宣布与辉瑞达成战略合作,通过Infinity智慧液体活检平台推动肿瘤新药的开发与商业化医药新闻-ByDrug-一站式医药资源共享中心-医药魔方: Revision history

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 December 2025

  • curprev 03:1203:12, 20 December 2025 ConcettaBoisvert talk contribs 8,400 bytes +8,400 Created page with "<br><br><br>【新闻事件】9月3日,Infinity制药公司宣布和艾伯维制药公司签署协议,合作开发并销售Infinity口服、选择性的PI3K δ/γ双重抑制剂Duvelisib。 Duvelisib目前正进行一个复发/难治性慢性淋巴细胞白血病(CLL)的三期临床实验,另一个和美罗华(利妥昔单抗)联合用药治疗滤泡性淋巴瘤的晚期实验,以及多个中早期临床研究也即将开展。 按照协议,Infinity支..."